AGF Management’s HCA Healthcare HCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$37.6M Buy
96,516
+11,933
+14% +$5.04M 0.15% 124
2026
Q1
$40M Sell
84,583
-3,124
-4% -$1.57M 0.18% 121
2025
Q4
$40.9M Sell
87,707
-1,169
-1% -$543K 0.18% 115
2025
Q3
$37.9M Buy
88,876
+2,018
+2% +$782K 0.17% 121
2025
Q2
$33.3M Sell
86,858
-1,572
-2% -$566K 0.15% 127
2025
Q1
$30.6M Buy
88,430
+4,177
+5% +$1.34M 0.16% 130
2024
Q4
$25.3M Buy
84,253
+5,756
+7% +$2.01M 0.13% 140
2024
Q3
$31.9M Sell
78,497
-1,263
-2% -$462K 0.16% 134
2024
Q2
$25.6M Sell
79,760
-7,659
-9% -$2.49M 0.14% 134
2024
Q1
$10.1M Sell
87,419
-3,926
-4% -$1.2M 0.06% 208
2023
Q4
$24.7M Buy
91,345
+86,163
+1,663% +$21.3M 0.15% 147
2023
Q3
$1.27M Buy
5,182
+1,623
+46% +$444K 0.01% 533
2023
Q2
$1.08M Sell
3,559
-2,652
-43% -$737K 0.01% 527
2023
Q1
$1.64M Buy
6,211
+1,741
+39% +$442K 0.01% 520
2022
Q4
$1.07M Buy
+4,470
New +$1M 0.01% 584

Other funds holding HCA

AGF Management's HCA Position: Q2 2026 in Review

AGF Management increased its HCA Healthcare (HCA) stake by 14% in Q2 2026, buying an estimated $5.04M and bringing the position to 96,516 shares worth $37.6M. The position accounts for 0.15% of the portfolio, ranked #124.

AGF Management first reported a position in HCA in Q4 2022 and has held it in 15 quarters since. The position peaked at $40.9M in Q4 2025. 1,338 funds tracked by Wall St. Rank hold HCA as of Q2 2026.

  • AGF Management held 96,516 shares of HCA Healthcare worth $37.6M as of Q2 2026.
  • AGF Management bought 11,933 HCA Healthcare shares in Q2 2026, an estimated $5.04M.
  • HCA Healthcare made up 0.15% of AGF Management's portfolio in Q2 2026, its #124 holding.
  • AGF Management first reported a position in HCA Healthcare in Q4 2022 and has held it in 15 quarters since.
  • AGF Management's HCA Healthcare position peaked at $40.9M in Q4 2025.
  • 1,338 funds tracked by Wall St. Rank held HCA Healthcare as of Q2 2026.

Based on AGF Management's 13F filing for Q2 2026, filed 10 Aug 2026.